You are here : Home > Theranexus signs partnership with the Collège de France

Academic partnerships | Pharmacology | Brain


Theranexus signs partnership with the Collège de France

Theranexus, a CEA-born biopharmaceutical company, signs a three-year research partnership agreement with the Collège de France.

Published on 15 March 2018

While working at the François Jacob Institute of Biology, Franck Mouthon and Mathieu Charveriat discovered the important role played by non-neuronal cells, called glial cells, in the neuronal response to psychotropic medications. Their seminal research showed that by modulating the organization of glial cells, it is possible to greatly improve neuronal response to and in turn the effectiveness of psychotropic medications. That research also moved them to co-found and share the direction of Theranexus, a company now joining forces with the Collège de France for a three-year joint research effort.

That collaboration will focus on the impact of glial cells on neuronal activity. Dr. Nathalie Rouach will supervise the research, to be carried out at the Center of Interdisciplinary Research in Biology directed by Prof. Alain Prochiantz. 

This research program will include a National Association for Research and Technology (ANRT) doctoral fellowship program (Cifre).

Top page